• Connect with us
  • Information
    • About Us
    • Contact Us
    • Careers
    • Partnerships
    • Advertise With Us
    • Authors
    • Browse Topics
    • Events
    • Disclaimer
    • Privacy Policy
  • NORTH AMERICA EDITION
    Australia
    North America
    World
Login
Investing News NetworkYour trusted source for investing success
  • NORTH AMERICA EDITION
    North America
    Australia
    World
  • My INN
Videos
Companies
Press Releases
Private Placements
SUBSCRIBE
  • Reports & Guides
    • Market Outlook Reports
    • Investing Guides
  • Button
Resource
  • Precious Metals
  • Battery Metals
  • Base Metals
  • Energy
  • Critical Minerals
Tech
Life Science
Genetics Market
Genetics News
Genetics Stocks
  • Genetics Market
  • Genetics News
  • Genetics Stocks

GenomeFIRST Awarded $400K Grant to Bring Genomic Information into Patients' Care Plans

Vivien Diniz
Feb. 02, 2016 10:12AM PST
Genetics Investing

Geisinger Health System has been awarded a $400,000 grant from the Robert Wood Johnson Foundation (RWJF) to support GenomeFIRST Medicine, a unique program to help patients and providers understand and use genomic information in their health care.

Geisinger Health System has been awarded a $400,000 grant from the Robert Wood Johnson Foundation (RWJF) to support GenomeFIRST Medicine, a unique program to help patients and providers understand and use genomic information in their health care.
According to the press release:

The GenomeFIRST Medicine program takes a comprehensive approach to care that includes genomic screening, interpretation and managing results — essentially changing health care by expanding providers’ ability to care for their patients before a problem arises. With support from the Robert Wood Johnson Foundation, Geisinger will pilot a scalable model for integrating genomic results into the everyday care of 300 Geisinger patients. The project will focus on the three most common genetic conditions in Geisinger’s GenomeFIRST program: Hereditary Breast and Ovarian Cancer Syndrome (HBOC), Lynch Syndrome, and Familial Hypercholesterolemia.

Dr. Michael Murray, director of clinical genomics, Geisinger Genomic Medicine Institute commented:

As we enter the era of precision health, we will increasingly use genetic information to identify health risk and then use preventive strategies to avoid disease. This program is building the infrastructure to do that. At Geisinger, we strongly believe that genome sequencing will become more and more integrated into routine care, and that GenomeFIRST Medicine will drive medicine toward early diagnoses and disease prevention for many of our patients.

Click here to view the full press release. 

genomic medicine
The Conversation (0)

Go Deeper

AI Powered
Senior woman doing exercises alongside closeup of DNA.

5 US Longevity and Anti-aging Stocks to Watch

A floating DNA double helix above a hand with a blue background.

Top 4 NASDAQ Genetics Stocks (Updated January 2026)

Latest News

Outlook Reports

Resource
  • Precious Metals
    • Gold
    • Silver
  • Battery Metals
    • Lithium
    • Cobalt
    • Graphite
    • Electric Vehicles
  • Agriculture
  • Base Metals
    • Copper
    • Nickel
    • Zinc
  • Critical Metals
    • Rare Earths
  • Energy
    • Uranium
    • Oil and Gas
Tech
    • Artificial Intelligence
    • Cybersecurity
    • Robotics
    • Crypto
    • Cleantech
Life Science
    • Biotech
    • Cannabis
    • Pharmaceuticals

Featured Stocks

More featured stocks

Browse Companies

Resource
  • Precious Metals
  • Battery Metals
  • Energy
  • Base Metals
  • Critical Metals
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES